In fact, trastuzumab (Herceptin®) is a monoclonal therapeutic antibody against breast cancer that targets erbB-2 by interacting with the CR2 domain, thus preventing erbB-2 dimerisation (Figure 3a). The gene discussed is ERBB2; the disease is breast carcinoma.